XENOBIOTICA
7
Disclosure statement
The authors have declared no conflict of interest.
References
Bernhardt R, Urlacher VB. (2014). Cytochromes P450 as promising cata-
lysts for biotechnological application: chances and limitations. Appl
Microbiol Biotechnol 98:6185–203.
Chen W, Li J, Sun Z, et al. (2018). Comparative pharmacokinetics of six
coumarins in normal and breast cancer bone-metastatic mice after
oral administration of Wenshen Zhuanggu formula. J Ethnopharmacol
2
24:36–44.
ꢀ
Crespi CL, Miller VP. (1997). The R144C change in the CYP2C9 2 allele
alters interaction of the cytochrome P450 with NADPH:cytochrome
P450 oxidoreductase. Pharmacogenetics 7:203–10.
Daniel WA, Haduch A, Syrek M, et al. (2006). Direct and indirect interac-
tions between antidepressant drugs and CYP2C6 in the rat liver dur-
ing long-term treatment. Eur Neuropsychopharmacol 16:580–7.
Doggrell SA. (2004). Inhibition of cardiac cytochrome P450: a new
approach to cardiac ischaemia and reperfusion damage. Expert Opin
Ther Targets 8:491–3.
Figure 5. Pharmacokinetics of indomethacin in rats. Fourteen SD male rats
were randomly divided into a drug administration group and a control group,
with seven rats in each group. Osthole (20 mg/kg) was administered orally to
drug group rats, while the control group was given the same concentration of
saline. The indomethacin (10 mg/kg) was administered orally in a control or
drug group rats. Each point represents the mean of six independent Du R, Xue J, Wang HB, et al. (2011). Osthol ameliorates fat milk-induced
determinations.
fatty liver in mice by regulation of hepatic sterol regulatory element-
binding protein-1c/2-mediated target gene expression. Eur
J
Pharmacol 666:183–8.
Table 1. Pharmacokinetic parameters of indomethacin in control group rats
(
received saline) or drug group rats (received 20 mg/kg for osthole) for seven Garcia-Martin E, Martinez C, Ladero JM, et al. (2006). Interethnic and
consecutive days.
intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in
healthy individuals. Mol Diagn Ther 10:29–40.
Gotoh O. (1992). Substrate recognition sites in cytochrome P450 family 2
PK parameters
Control group (n ¼ 7)
Osthole
–
1
AUC0–1 (lg/ml h
)
176.40 ± 17.29
9.02 ± 1.24
2.00 ± 0.00
8.38 ± 2.30
0.11 ± 0.01
173.74 ± 27.69
9.89 ± 0.82
7.33 ± 1.15
11.37 ± 2.11
0.12 ± 0.04
(
CYP2) proteins inferred from comparative analyses of amino acid and
Cmax (lg/ml)
ꢀ
ꢀ
coding nucleotide sequences. J Biol Chem 267:83–90.
He L, Li C, Liu X, et al. (2017). Comparative study on the interaction
between 3 CYP2C9 allelic isoforms and benzbromarone by using
LC–MS/MS method. J Chromatogr B Analyt Technol Biomed Life Sci
1070:97–103.
He SM, Zhou ZW, Li XT, et al. (2011). Clinical drugs undergoing poly-
morphic metabolism by human cytochrome P450 2C9 and the impli-
cation in drug development. Curr Med Chem 18:667–713.
Hiratsuka M. (2016). Genetic polymorphisms and in vitro functional char-
acterization of CYP2C8, CYP2C9, and CYP2C19 allelic variants. Biol
Pharm Bull 39:1748–59.
T
max (h)
T1/2 (h)
CL/F (mg/kg/h)
The concentration of saline is 0.9%. The doses of indomethacin in the control
group and the drug group were 10 mg/kg. Data are expressed as mean ± SD
of seven rats.
AUC: area under the curve; Cmax: maximum concentration; Tmax: time to reach
peak plasma concentrations;
T
1/2
:
elimination half-life; CL/F: appar-
ent clearance.
ꢀ
p < 0.05 compared with the control group.
Huang LH, Zhong YM, Xiong XH, et al. (2016). The disposition of oxyma-
trine in the vascularly perfused rat intestine-liver preparation and its
metabolism in rat liver microsomes. J Pharm Sci 105:897–903.
experimental group, and found that the area under the curve
(
AUC), Cmax, CL/F (apparent clearance) are not changed, but
Tmax, T1/2 are extended, which indicates that osthole affects Jarz a˛ b A, Grabarska A, Skalicka-Wo ꢀz niak K, et al. (2017). Pharmacological
features of osthole. Postepy Hig Med Dosw 71:411–421.
Jiang G, Liu J, Ren B, et al. (2016). Anti-tumor effects of osthole on ovar-
ian cancer cells in vitro. J Ethnopharmacol 193:368–76.
Kara ꢀz niewicz-Łada M, Łuczak M, Gł oꢀ wka F. (2009). Pharmacokinetic stud-
the pharmacokinetics of indomethacin in vivo, but not the
CYP2C9-mediated metabolism. The delay in Tmax may be due
to the effect of osthole on gastrointestinal peristalsis (Chen
et al., 2018). As there are many experimental differences
between in vitro and in vivo, we need further study for
explaining the processes.
In conclusion, we investigated the inhibition of osthole on
CYP2C11/CYP2C9 enzyme in vitro and in vivo and found indi-
ies of enantiomers of ibuprofen and its chiral metabolites in humans
with different variants of genes coding CYP2C8 and CYP2C9 isoen-
zymes. Xenobiotica 39:476–85.
Kim SH, Kim DH, Byeon JY, et al. (2017). Effects of CYP2C9 genetic poly-
morphisms on the pharmacokinetics of celecoxib and its carboxylic
acid metabolite. Arch Pharm Res 40:382–90.
vidual differences and species differences affect the process. Kirchheiner J, Bauer S, Meineke I, et al. (2002). Impact of CYP2C9 and
The results suggest that we should pay attention to the
inhibition of osthole on CYP2C9 enzyme in experiment and
clinical studies. Individual differences and differences in spe-
cies has influenced pharmacokinetic of indomethacin in vivo,
which indicates that we need to care the use of osthole in
CYP2C19 polymorphisms on tolbutamide kinetics and on the insulin
and glucose response in healthy volunteers. Pharmacogenetics 12:
101–9.
Liang HJ, Suk FM, Wang CK, et al. (2009). Osthole, a potential antidia-
betic agent alleviates hyperglycemia in db/db mice. Chem Biol
Interact 181:309–15.
combination with other drugs, particularly, we should pay Lowry OH, Rosebrough NJ, Farr AL, et al. (1951). Protein measurement
with the Folin phenol reagent. Biol Chem 193:265–75.
McGraw J, Waller M. (2012). Cytochrome P450 variations in different eth-
nic populations. Expert Opin Drug Metab Toxicol 8:371–82.
Pan Z, Fang Z, Lu W, et al. (2015). Osthole, a coumadin analog from
Cnidium monnieri (L.) Cusson, stimulates corticosterone secretion by
attention to the risk of using the drug in patients with
ꢀ
ꢀ
CYP2C9 2 and CYP2C9 3. Only in this way, we can reduce
adverse reactions and avoid the occurrence of drug–drug
interactions.